Qian S, Fu F, Li Y, Lu L, Rao A S, Starzl T E, Thomson A W, Fung J J
Department of Surgery, University of Pittsburgh Medical Center, PA, USA.
Immunology. 1996 May;88(1):124-9. doi: 10.1046/j.1365-2567.1996.d01-633.x.
The influence of donor major histocompatibility complex (MHC) class I- or class II-deficiency on the initiation of first- and second-set rejection of mouse heart and liver allografts was examined. C3H (H-2k) mice received heterotopic cardiac or orthotopic liver grafts from unmodified B10 (H-2b), B6 (H-2b), b2m (H-2b; class I deficient) or AB0 (H-2b; class II deficient) donors. Organ survival was also investigated in C3H recipients that had been presensitized by a normal B10 skin graft 2-3 weeks before heart or liver transplantation. The absence of cell surface MHC class I or class II resulted in significant prolongation of primary cardiac allograft survival. Three of seven (43%) MHC class I-deficient, and two of five (40%) class II-deficient heart grafts were accepted indefinitely (survival time > 100 days). Thus both MHC class I and class II molecules appear to be important for the elicitation of first-set rejection in the heart allograft model. All liver allografts survived > 100 days in normal recipients. In C3H recipients that had been presensitized by a B10 skin graft, however, both heart and liver grafts from AB0 (class II deficient) donors underwent accelerated rejection (median survival time [MST] 3 and 4 days, respectively). In contrast, liver grafts from class I-deficient mice (b2m) were still accepted indefinitely by B10 skin-presensitized C3H recipients, whereas class I-deficient hearts survived significantly longer than those from class II-deficient or normal donors. These data demonstrate that the expression of donor MHC class I, and not class II is crucial in initiating second-set organ allograft rejection. In vitro monitoring revealed that at the time of organ transplant, both splenocytes and serum of the skin-presensitized animals displayed high cytotoxicity against AB0 (class II-deficient) but not against b2m (class I-deficient) targets.
研究了供体主要组织相容性复合体(MHC)Ⅰ类或Ⅱ类缺陷对小鼠心脏和肝脏同种异体移植首次和二次排斥反应启动的影响。C3H(H-2k)小鼠接受来自未修饰的B10(H-2b)、B6(H-2b)、b2m(H-2b;Ⅰ类缺陷)或AB0(H-2b;Ⅱ类缺陷)供体的异位心脏或原位肝脏移植。还研究了在心脏或肝脏移植前2-3周经正常B10皮肤移植预先致敏的C3H受体的器官存活情况。细胞表面MHCⅠ类或Ⅱ类的缺失导致原发性心脏同种异体移植存活时间显著延长。7个Ⅰ类缺陷心脏移植中有3个(43%)、5个Ⅱ类缺陷心脏移植中有2个(40%)被无限期接受(存活时间>100天)。因此,MHCⅠ类和Ⅱ类分子似乎对心脏同种异体移植模型中首次排斥反应的引发都很重要。所有肝脏同种异体移植在正常受体中存活>100天。然而,在经B10皮肤移植预先致敏的C3H受体中,来自AB0(Ⅱ类缺陷)供体的心脏和肝脏移植均发生加速排斥反应(中位存活时间[MST]分别为3天和4天)。相比之下,来自Ⅰ类缺陷小鼠(b2m)的肝脏移植仍被经B10皮肤预先致敏的C3H受体无限期接受,而Ⅰ类缺陷心脏的存活时间明显长于Ⅱ类缺陷或正常供体的心脏。这些数据表明,供体MHCⅠ类而非Ⅱ类的表达在启动二次器官同种异体移植排斥反应中至关重要。体外监测显示,在器官移植时,皮肤预先致敏动物的脾细胞和血清对AB0(Ⅱ类缺陷)靶细胞显示出高细胞毒性,但对b2m(Ⅰ类缺陷)靶细胞则无此毒性。